Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
ID: 356515Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356515

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-299.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) aimed at advancing research in behavioral and integrative treatments for substance use and dependence. This program encourages the development and testing of innovative behavioral therapies through a structured approach that includes intervention generation, efficacy testing in research settings, and real-world efficacy assessments, with a focus on diverse populations and the use of technology. The funding amount is contingent on NIH appropriations, with a maximum project period of five years, and applications are due by February 5, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-299.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-299.html
    The Department of Health and Human Services' National Institutes of Health (NIH) is announcing a funding opportunity titled the Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional) aimed at advancing research in behavioral and integrative treatments for substance use and dependence. This initiative focuses on the development and testing of new and modified behavioral therapies, structured in three stages: Stage I involves intervention generation and pilot testing; Stage II relates to efficacy testing in research settings; and Stage III assesses efficacy in real-world settings. The announcement encourages research on effective treatments tailored to diverse populations, utilizing innovative technologies and pharmacotherapies. Eligible applicants include various educational institutions, nonprofits, and local governments, with an application deadline of February 5, 2025. The funding amount is contingent on NIH appropriations and project needs, with a maximum project period of five years. The overall goal is to translate scientific findings into effective, accessible interventions for substance use disorders.
    Similar Opportunities
    Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) aimed at promoting research for innovative behavioral and integrative treatments for drug and alcohol use disorders. This initiative encourages the development and testing of interventions across various stages, from initial generation and refinement to efficacy testing in controlled and real-world settings, focusing on enhancing treatment efficacy and accessibility, particularly in community environments. Applications are welcomed from a diverse range of organizations, including higher education institutions and for-profit entities, with no budget limit specified, and must be submitted by March 21, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-182.html.
    Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), a federal grant opportunity aimed at funding research for developing and testing behavioral treatments for substance use and dependence. This initiative seeks to encourage research that tests the efficacy of behavioral interventions, examines mechanisms of behavior change, and optimizes treatment approaches, particularly for individuals with comorbidities and those in drug abuse treatment. The program is crucial for advancing substance abuse treatment and addressing health disparities, with a maximum funding amount of $450,000 available over three years. Interested applicants, including various educational institutions and community organizations, must submit their proposals by March 21, 2025, and can find additional information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at encouraging clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) related to substance use disorders (SUD). This initiative seeks exploratory and developmental studies that may involve significant risks but have the potential to lead to breakthroughs in understanding the neurobiological and behavioral responses associated with SUD treatment. The funding opportunity includes a budget cap of $600,000 for the R61 phase, with a total of up to $1.5 million available across multiple awards, and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the application period opens on December 16, 2023, and closes on August 14, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)" aimed at advancing research in the treatment and recovery from alcohol use disorder (AUD). This grant supports clinical trials focusing on various aspects of AUD, including medication development, behavioral therapies, and innovative treatment technologies, particularly for populations facing health disparities. The funding is crucial for enhancing the understanding and efficacy of AUD treatments, ultimately contributing to improved public health outcomes. Eligible applicants can receive up to $500,000 in direct costs over a maximum project period of five years, with key submission deadlines on October 5, 2023, and February 5, 2024. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-250.html.